Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Avalo Therapeutics Inc (AVTX)

Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum GlobeNewswire - Tue Jul 7, 6:00AM CDT

WAYNE, Pa., July 07, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes GlobeNewswire - Fri Jun 26, 6:00AM CDT

WAYNE, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Appoints Ron Philip to Board of Directors GlobeNewswire - Tue Jun 23, 6:00AM CDT

WAYNE, Pa., June 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody GlobeNewswire - Tue Jun 16, 6:00AM CDT

IND submission for AVTX-010 planned for the first half of 2027 WAYNE, Pa., June 16, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri May 22, 3:01PM CDT

WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates GlobeNewswire - Wed May 13, 6:00AM CDT

Achieved positive topline results in Phase 2 LOTUS trial of abdakibart in moderate to severe hidradenitis suppurativa (HS) and plan to advance into a registrational phase 3 program Completed public...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It Barchart - Sat May 9, 4:00PM CDT

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Reports First Results Since LOTUS Trial Success Changed Everything—Or Did It Barchart - Fri May 8, 4:02PM CDT

Barchart Research What to Expect from AVTX Earnings AVTX Generated May 8, 2026 Current Price $21.57 EPS Estimate $$-1.00 Consensus Rating Strong Buy Average Move 3.29% Avalo Therapeutics Reports First...

AVTX : 19.21 (-0.21%)
Avalo Therapeutics Announces Pricing of $375 Million Public Offering GlobeNewswire - Tue May 5, 10:33PM CDT

WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated...

AVTX : 19.21 (-0.21%)

Barchart Exclusives

Nike’s Dividend Yield Is Near Record Highs, But That’s Not a Good Enough Reason to Buy NKE Stock Barchart - Wed Jul 8, 6:30PM CDT
Nike's dividend yield is nearly 3.8%, which is near the record highs we saw last month. That, however, does not make the stock a buy. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.